Ichor is dedicated to the clinical application and commercialization of electroporation-mediated DNA drug delivery. Electroporation's safety has been established in multiple clinical trials for delivery of chemotherapeutics for certain types of cancer. Extensive preclinical studies of in vivo electroporation-mediated DNA drug delivery done at Ichor have demonstrated that the technique can enable targeted uptake and expression of naked DNA plasmids encoding DNA vaccines as well as therapeutic genes.

Ichor’s proprietary TriGrid™ Delivery System uses electrical fields to increase DNA drug delivery efficiency by up to 1,000 fold. While a number of approaches have been used for electroporation-mediated DNA drug delivery in pre-clinical models, clinical implementation has been hindered by the lack of a reliable and effective means for procedure administration. Ichor’s TriGrid™ Delivery System platform integrates several patented electroporation technologies into a simple handheld clinical device that enables safe, efficient, and reproducible DNA administration and delivery with minimal operator training.